Thursday, July 06, 2006

Drug for Resistant Lamividine Drug Therapy against HBV

The greatest challenge faced against treatment of Hepatitis B virus (HBV) was the resistance to lamividine drug therapy. In a prospective, randomized, controlled trial, patients with lamivudine resistance HBeAg-positive chronic HBV infection were randomly assigned to either receive the entecavir (Baraclude) or remain on lamivudine for at least 48 weeks.

All the patients were analyzed by their HBV DNA copies and by a Knodell fibrosis score. The relationship between efficacy and baseline disease and demographic characteristics was assessed.
After 48 weeks, patients who received entecavir experienced HBV DNA reduction of 5.11 log10 copies/mL, compared with a reduction of 0.48 log10 copies/mL among patients receiving lamivudine. Patients that were taking entecavir experience histological improvement compared to those taking lamivudine (55% vs 28% respectively).

This is another great wonder drug and specific for Hepatitis B. This will help the strain that is resistant to lumivudine hepatitis B drug therapy and reduce the chronic conditions of Hepatitis B to almost non-existence. I wish this drug was around when my dad was suffering from HBV so that he might be able to get through his illness and be alive today. The more I learn about this disease, the more I wonder about my dad’s prognosis. I was too young to understand or even know about the disease itself. More questions when I found a few answers.


Post a Comment

<< Home